Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
$2.37
-4.4%
$2.55
$1.09
$6.56
$168.67M2.941.58 million shs2.48 million shs
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
$14.10
-5.5%
$11.33
$1.92
$19.39
$744.76M2.67532,164 shs1.47 million shs
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
$13.83
+0.7%
$15.28
$9.12
$72.37
$561.78M0.97901,665 shs660,465 shs
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$7.75
-4.7%
$7.87
$4.55
$8.98
$623.49M1.34493,604 shs309,896 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
+11.71%+2.90%-27.27%+6.90%-64.57%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
+0.27%+10.11%+59.91%+170.29%+397.33%
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
-5.18%-14.76%-13.04%-0.07%-77.90%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-0.12%-7.19%+11.07%-5.68%+37.33%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
$2.37
-4.4%
$2.55
$1.09
$6.56
$168.67M2.941.58 million shs2.48 million shs
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
$14.10
-5.5%
$11.33
$1.92
$19.39
$744.76M2.67532,164 shs1.47 million shs
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
$13.83
+0.7%
$15.28
$9.12
$72.37
$561.78M0.97901,665 shs660,465 shs
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$7.75
-4.7%
$7.87
$4.55
$8.98
$623.49M1.34493,604 shs309,896 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
+11.71%+2.90%-27.27%+6.90%-64.57%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
+0.27%+10.11%+59.91%+170.29%+397.33%
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
-5.18%-14.76%-13.04%-0.07%-77.90%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-0.12%-7.19%+11.07%-5.68%+37.33%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
2.43
Hold$8.50258.65% Upside
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
2.00
Hold$13.20-6.38% Downside
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
2.40
Hold$30.00116.92% Upside
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
2.33
Hold$24.00209.68% Upside

Current Analyst Ratings Breakdown

Latest CCCC, KROS, MGTX, and KOD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2025
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
10/8/2025
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
10/8/2025
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/6/2025
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$14.00
9/27/2025
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/27/2025
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
9/27/2025
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/25/2025
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeUnderweightEqual Weight$7.00 ➝ $17.00
9/23/2025
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$5.00 ➝ $10.00
(Data available from 10/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
$35.58M4.74N/AN/A$3.06 per share0.77
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/AN/AN/AN/A$2.86 per shareN/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
$3.55M158.25N/AN/A$14.11 per share0.98
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$33.28M18.73N/AN/A$0.87 per share8.91
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-$105.32M-$1.58N/AN/AN/A-325.88%-53.91%-33.26%10/30/2025 (Estimated)
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$176.21M-$3.80N/AN/AN/AN/A-155.27%-63.29%11/13/2025 (Estimated)
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
-$187.35M$0.3144.61N/A1.878.06%2.96%2.74%11/5/2025 (Estimated)
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$147.79M-$2.04N/A20.39N/A-415.39%-314.44%-63.28%11/12/2025 (Estimated)

Latest CCCC, KROS, MGTX, and KOD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/13/2025Q3 2025
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$1.06N/AN/AN/AN/AN/A
11/12/2025Q3 2025
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$0.51N/AN/AN/A$7.71 millionN/A
11/5/2025Q3 2025
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
-$1.11N/AN/AN/A$4.22 millionN/A
10/30/2025Q3 2025
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-$0.43N/AN/AN/AN/AN/A
8/14/2025Q2 2025
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$0.52-$0.48+$0.04-$0.48$8.00 million$3.69 million
8/13/2025Q2 2025
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$1.01-$1.03-$0.02-$1.03N/AN/A
8/7/2025Q2 2025
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-$0.38-$0.37+$0.01-$0.37$5.24 million$6.46 million
8/6/2025Q2 2025
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
-$1.14-$0.76+$0.38-$0.76$3.83 million$0.02 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
N/AN/AN/AN/AN/A
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/AN/AN/AN/AN/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
N/AN/AN/AN/AN/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
N/A
5.06
5.06
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/A
3.48
3.48
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
N/A
21.11
21.11
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
26.29
0.88
0.88

Institutional Ownership

CompanyInstitutional Ownership
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
78.81%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
89.06%
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
71.56%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
67.48%

Insider Ownership

CompanyInsider Ownership
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
8.73%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
45.90%
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
20.60%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
7.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
15071.17 million64.96 millionOptionable
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
9052.82 million28.58 millionOptionable
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
10040.62 million32.25 millionOptionable
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
30080.45 million74.41 millionOptionable

Recent News About These Companies

MeiraGTx Sales Jump 1,133 Percent
MeiraGTx Holdings plc (MGTX) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

C4 Therapeutics stock logo

C4 Therapeutics NASDAQ:CCCC

$2.37 -0.11 (-4.44%)
Closing price 04:00 PM Eastern
Extended Trading
$2.41 +0.04 (+1.69%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Kodiak Sciences stock logo

Kodiak Sciences NASDAQ:KOD

$14.10 -0.82 (-5.50%)
Closing price 04:00 PM Eastern
Extended Trading
$14.10 0.00 (0.00%)
As of 04:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Keros Therapeutics stock logo

Keros Therapeutics NASDAQ:KROS

$13.83 +0.09 (+0.66%)
Closing price 04:00 PM Eastern
Extended Trading
$13.83 0.00 (0.00%)
As of 04:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

MeiraGTx stock logo

MeiraGTx NASDAQ:MGTX

$7.75 -0.38 (-4.67%)
Closing price 04:00 PM Eastern
Extended Trading
$7.74 0.00 (-0.06%)
As of 04:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.